Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) shares fell 8.1% during trading on Tuesday . The stock traded as low as $2.75 and last traded at $2.85. 2,377 shares were traded during trading, a decline of 43% from the average session volume of 4,197 shares. The stock had previously closed at $3.10.
Cyclerion Therapeutics Stock Down 8.1 %
The firm’s 50 day moving average is $2.98 and its two-hundred day moving average is $2.92.
Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.53) earnings per share for the quarter.
Hedge Funds Weigh In On Cyclerion Therapeutics
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
See Also
- Five stocks we like better than Cyclerion Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- Using the MarketBeat Stock Split Calculator
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.